The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Provident Financial Up On Better Outlook

Wed, 26th Aug 2020 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - WINNERS

----------

Aveva Group, up 3.5%. The industrial software company was extending gains after announcing on it had agreed to buy US rival OSIsoft for USD5 billion. The stock closed up 7.3% on Tuesday.

----------

FTSE 100 - LOSERS

----------

Polymetal International, down 0.5%. Shares were lower despite the Russian gold miner doubling its interim dividend as a much higher gold price boosted performance. Revenue jumped 17% to USD1.14 billion from USD941 million, and net earnings more than doubled to USD381 million from USD153 million. Polymetal declared a USD0.40 per share interim dividend, twice its USD0.20 per share dividend the year before. The stock remains 62% higher so far in 2020.

----------

FTSE 250 - WINNERS

----------

Provident Financial, up 17%. The subprime lender's shares were sharply higher despite swinging to an interim loss and scrapping its dividend. For the six months ended June 30, Provident swung to a pretax loss of GBP28 million from a profit of GBP43.1 million a year prior. This was as revenue fell 11% to GBP445.6 million from GBP501.5 million. No interim dividend was declared, compared to 9.0p paid for the first half of 2020, as Provident said it needs to preserve capital and provide financial stability. However, Provident said it built strong capital and liquidity positions during the period, with regulatory capital of GBP705 million at the end of June. This equates to a CET1 ratio of 35.4% and a surplus of GBP215 million above the minimum regulatory requirement. Looking ahead, Provident noted since the end of June, there were some encouraging signs of increased activity levels in its markets, with improving customer demand and spending trends evident.

----------

Inchcape, up 5.0%. JPMorgan raised the car dealer to Overweight from Neutral.

----------

Go-Ahead Group, up 4.1%. The transport operator said the Land Transport Authority of Singapore has granted a two-year extension to the contract allowing its Singaporean arm to continue bus operations. Go-Ahead said the extension allows it to continue operating around 450 buses in the Loyang region, which is in the east of the island near Singapore Changi Airport. The extension will begin in September 2021 and run until September 2023. This follows the initial five-year contract which saw the company's entry into the Singapore bus market in September 2016, Go-Ahead said.

----------

WH Smith, up 3.0%. Goldman Sachs started coverage on the books and stationery retailer with a Buy rating.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

4D Pharma, up 32%. The pharmaceutical company said results of Part A of its Phase I/II trial of MRx0518 in combination with immune checkpoint inhibitor Keytruda were "extremely encouraging". MRx0518 is single strain live biotherapeutic product in development for the treatment of cancer. 4D said in 12 patients with metastatic renal cell carcinoma and metastatic non-small cell lung cancer, the combination of MRx0518 with Keytruda achieved a disease control rate of 42%, with five of the 12 patients experiencing a clinically meaningful benefit from the combination. Three patients saw their tumours shrink by around 30%.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Vela Technologies, down 43%. The suspension of trading in Vela shares was lifted on Wednesday after the tech investor completed a capital restructure. Vela on Monday got approval from share and bond holders for disposal of some assets, plus a share capital reorganisation and the conversion of GBP550,000 of outstanding bonds to shares, as well as a GBP1.0 million share placing. The Bingley-headquartered company's suspension on AIM was lifted with bond conversion shares, placing shares, fee shares, broker shares, and new ordinary shares all admitted to trading. Following admission, Vela has 7.17 billion shares in issue.

----------

Pebble Beach Systems Group, down 17%. The software firm said Covid-19 hit its order intake in the first six months of 2020, with customers a bit more cautious about pursuing large projects. In the period to June 30, Pebble Beach's revenue fell 20% year-on-year to GBP4.5 million from GBP5.6 million. Pretax profit, however, rose 3.4% to GBP739,000 from GBP715,000. Sales and marketing expenses were trimmed by 14% to GBP901,000, research and development expenses by 16% to GBP605,000, and administrative costs by 15% to GBP878,000. Orders received were 26% lower during the half at GBP3.9 million from GBP5.2 million a year earlier.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
16 May 2019 09:59

4d Pharma To Present Data From Thetanix Clinical Study In San Diego

LONDON (Alliance News) - 4d Pharma PLC on Thursday said it will present the data from the completed phase Ib clinical study of Thetanix for the treatment of Crohn's disease on Saturday in San

Read more
29 Apr 2019 09:20

4d Pharma "Delighted" With Progress Being Made On Oncology Programme

LONDON (Alliance News) - 4d Pharma PLC on Monday reported a positive initial phase of one drug trial and the start of another.In a phase I/II trial of pembrolizumab, or Keytruda, the first

Read more
14 Mar 2019 09:53

DIRECTOR DEALINGS: 4D Pharma CEO And Chief Scientific Officer Buy

LONDON (Alliance News) - 4D Pharma PLC on Thursday said Chief Scientific Officer Alex Stevenson purchased 24,896 shares at a price of 91.5 pence each on Wednesday for a total of in 4D Pharma were

Read more
13 Mar 2019 15:36

DIRECTOR DEALINGS: 4d Pharma Non-Exec Chair And Director Buy Shares

LONDON (Alliance News) - 4d Pharma PLC on Wednesday said Non-Executive Chair David Norwood and Non-Executive Director Thomas Engelen both purchased shares in the AIM-listed pharmaceutical separate

Read more
29 Jan 2019 09:26

4D Pharma Reports Reveals MRx0518 Immune System Stimulatory Effect

LONDON (Alliance News) - 4D Pharma PLC said Tuesday tests have shown its MRx0518 cancer treatment has "strong immuno-stimulatory effects".Researchers at 4D demonstrated that - on

Read more
8 Jan 2019 10:57

4D Pharma Appoints Two Non-Executives From Xencor And Celgene

LONDON (Alliance News) - 4D Pharma PLC said Tuesday it has appointed two new independent non-executive directors, one a previous chief business officer at Xencor Inc and the other a former senior

Read more
7 Jan 2019 08:20

4d Pharma buoyed by Texas cancer treatment partnership

(Sharecast News) - 4d Pharma's shares enjoyed a boost on Monday after entering a collaboration with a specialist cancer unit at the University of Texas.

Read more
7 Jan 2019 07:57

4D Pharma Partners With Cancer Center For Cancer Treatment

LONDON (Alliance News) - 4D Pharma PLC on Monday said it has partnered with the University of Texas MD Anderson Cancer Center to evaluate its live biotherapeutic oncology pipeline.The will

Read more
12 Dec 2018 09:19

4d Pharma "Not Aware Of Matter" Responsible For Drop In Share Price

LONDON (Alliance News) - 4d Pharma PLC on Wednesday noted a recent fall in its share price, but said is not aware of any company-related reasons for the drop.The pharmaceutical company that

Read more
28 Sep 2018 10:41

4d Pharma Interim Loss Holds Steady Despite Rise In R&D Spending

LONDON (Alliance News) - 4d Pharma PLC on Friday said its loss widened only marginally in the first half of the year, despite significantly higher expenses, due to the absence of a non-recurring a

Read more
28 Sep 2018 08:29

4d Pharma losses little changed as trials begin

(Sharecast News) - First-half losses grew slightly at live biotherapeutics developer 4d Pharma as first-half research and development expenses jumped ahead of two of its major treatment candidates receiving clearance for clinical trials.

Read more
24 Sep 2018 14:19

Positive top-line results for 4D Pharma's Thetanix

(Sharecast News) - Biotherapeutics company 4D Pharma announced positive top-line results for its Phase 1b study of 'Thetanix' in paediatric patients with Crohn's disease on Monday.

Read more
24 Sep 2018 08:45

4d Pharma Reports Positive Results From Phase Ib Study Of Thetanix

LONDON (Alliance News) - 4d Pharma PLC on Monday said its phase Ib study of Thetanix in paediatric patients with Crohn's disease achieved its primary objective.Crohn's disease is a

Read more
12 Jun 2018 17:55

Janus Henderson Increases Stake In 4d Pharma To 5.2% (ALLISS)

LONDON (Alliance News) - 4d Pharma PLC said Janus Henderson Group PLC increased stake in the pharmaceutical company to 5.2% after a transaction on Tuesday.Janus Henderson raised its holding

Read more
21 May 2018 07:40

LONDON MARKET PRE-OPEN: FTSE 100 Set For All-Time Record At Open

LONDON (Alliance News) - The FTSE 100 is set to open at an all-time high on Monday, coming after trade tensions between the US and China eased over the weekend.In early UK company news on said the US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.